아르보바이러스 검사 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Arbovirus Testing Market Size, Share & Trends Analysis Report By Type (ELISA-Based Tests, RT-PCR Based Tests), By End-use (Diagnostic Laboratories, Hospitals, Research Centers), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,275,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,666,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,447,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

아르보바이러스 검사 시장 규모와 동향

세계의 아르보바이러스 검사 시장 규모는 2024년에 11억 2,000만 달러로 평가되었고, 2025-2030년에 걸쳐 CAGR 4.5%로 성장할 것으로 예측됩니다.

지카열, 뎅기열, 웨스트나일 등의 아르보바이러스 질환의 발생률이 상승하는 것이 견고한 검사 솔루션 수요를 촉진하고 있습니다. 관리를 위한 정확한 진단의 필요성이 높아지고 있습니다. 일반 시민과 헬스케어 시스템에 있어서의 인식의 증가는 서베이란스 활동의 개선으로 연결되어, 잠재적인 아웃브레이크에 대한 신속한 식별과 대응을 가능하게 하고 있습니다.

정부와 의료기관은 이러한 감염의 확산을 억제하기 위해 적시에 감지를 우선하기 때문입니다.

아르보바이러스 검사는 무시무시한 열대병(Neglected Tropical) Diseases : NTDs)의 확산을 막기위한 매우 중요한 도구로 떠오르고 있습니다. WHO 추정에 따르면, 인구의 약 5분의 1, 즉 주로 개발도상국과 저소득 국가에 거주하는 약 17억 명의 사람들이 매년 최소한 하나의 비감염성 질병에 대한 진단과 치료를 받아야 합니다. 이러한 질병은 바이러스 성장에 유리한 환경과 위생 부족으로 인해 열대 및 접근하기 어려운 지역의 빈곤한 지역 사회에서 많이 볼 수 있습니다. 대부분의 NTD 사례는 브라질, 예멘, 인도, 방글라데시, 중국 및 중앙아프리카와 동아프리카의 여러 국가에서 보고되고 있습니다. 따라서 뎅기열과 치쿤그니어의 발생률 증가는 알보 바이러스 검사 수요를 부추기고 시장 성장을 가속할 것으로 예측됩니다.

또한 미국 세계 건강 이니셔티브, 질병 대책 예방 센터에 의한 세계 NTD 프로그램, 세계 보건기구의 세계 NTD 프로그램, 미국 국제 개발청에 의한 NTD 프로그램 등 여러 국제기구가 NTD에 대한 인식을 높이기 위한 프로그램을 실시했습니다. 이 프로그램들은 주로 뎅기열과 치쿤구니야와 같은 NTD를 줄이거나 제거하는 데 중점을 둡니다. 또한 WHO는 2023년10 월에 NTDs에 대한 WHO 진단 전문가 심사 패널(ERPD) 파일럿 프로그램을 도입했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 아르보바이러스 검사 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련, 보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 아르보바이러스 검사 시장 분석 툴
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 아르보바이러스 검사 시장 : 유형별, 추정 및 예측 분석

• 유형 부문 대시보드
• 아르보바이러스 검사 시장 : 유형 변동 분석
• 세계의 아르보바이러스 검사 시장 규모와 동향 분석(유형별, 2018-2030년)
• ELISA 기반 검사
• RT-PCR 기반 검사
• 기타 검사 유형

제5장 아르보바이러스 검사 시장 : 최종 용도별, 추정 및 예측 분석

• 최종 용도 부문 대시보드
• 아르보바이러스 검사 시장 : 최종 용도 변동 분석
• 세계의 아르보바이러스 검사 시장 규모와 동향 분석(최종 용도별, 2018-2030년)
• 진단 실험실
• 병원
• 연구센터
• 기타

제6장 아르보바이러스 검사 시장 : 지역별, 추정 및 예측 분석

• 지역별 시장 대시보드
• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 아르보바이러스 검사 시장 : 주요 포인트
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업, 경쟁의 분류
• 벤더 상황
  • 주요 기업 히트맵 분석, 2024년
• 기업 프로파일
  • Abbott
  • Thermo Fisher Scientific Inc.
  • NovaTec Immundiagnostica GmbH(Gold Standard Diagnostics Frankfurt GmbH)
  • Agilent Technologies, Inc.
  • EUROIMMUN Medical Laboratory Diagnostics AG
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • QIAGEN
  • Bio-Rad Laboratories, Inc.

SHW

영문 목차

영문목차

Arbovirus Testing Market Size & Trends:

The global arbovirus testing market size was valued at USD 1.12 billion in 2024 and is expected to grow at a CAGR of 4.5% from 2025 to 2030. The rising incidence of arboviral diseases such as Zika, dengue, and West Nile is fueling the demand for robust testing solutions. The increasing prevalence of these diseases in various regions has heightened the need for accurate diagnostics to manage outbreaks effectively. Increased awareness among the public and healthcare systems has led to improved surveillance efforts, enabling faster identification and response to potential outbreaks.

This greater focus on disease monitoring drives the arbovirus testing market, as governments and health organizations prioritize timely detection to control the spread of these infections.

Arbovirus testing has emerged as a pivotal tool in preventing the spread of these Neglected Tropical Diseases (NTDs). According to WHO estimates, around one-fifth of the population-about 1.7 billion people, mostly in developing and low-income nations-must receive diagnosis and treatment for at least one noncommunicable disease annually. The dengue and chikungunya NTD epidemic impacted almost 40% of Africa. These illnesses are more common in impoverished communities in tropical and hard-to-reach locations due to a favorable environment for virus growth and lack of hygiene. Thus, most NTD cases are reported from Brazil, Yemen, India, Bangladesh, China and several countries in Central and East Africa. Thus, the rising incidence of dengue and chikungunya is anticipated to fuel the demand for arbovirus testing, thereby driving market growth.

Moreover, several international organizations run programs to raise awareness of NTDs, including the United States Global Health Initiative, the Global NTD Program by the Centers for Disease Control and Prevention, the World Health Organization's Global NTD Programs, and the NTD Program by the United States Agency for International Development. These programs focus mainly on reducing or eliminating NTDs such as dengue and chikungunya. In addition, the WHO introduced a pilot program for a WHO Expert Review Panel for Diagnostic Products (ERPD) for NTDs in October 2023. This program focuses on enhancing the quality control and availability of NTD diagnostic tools for medical professionals.

Global Arbovirus Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global arbovirus testing market report on the basis of type, end-use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• ELISA-based Tests
• RT-PCR Based Tests
• Other Test Types
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Diagnostic Laboratories
• Hospitals
• Research Centers
• Other End Use
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End Use
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Scenario

Chapter 3. Arbovirus Testing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Arbovirus Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape

Chapter 4. Arbovirus Testing Market: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Arbovirus Testing Market: Type Movement Analysis
• 4.3. Global Arbovirus Testing Market Size & Trend Analysis, By Type, 2018 to 2030 (USD Million)
• 4.4. ELISA-Based Tests
  • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.5. RT-PCR Based Tests
  • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 4.6. Other Test Types
  • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Arbovirus Testing Market: End Use Estimates & Trend Analysis

• 5.1. End Use Segment Dashboard
• 5.2. Arbovirus Testing Market: End Use Movement Analysis
• 5.3. Global Arbovirus Testing Market Size & Trend Analysis, By End Use, 2018 to 2030 (USD Million)
• 5.4. Diagnostic Laboratories
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.5. Hospitals
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.6. Research Centers
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 5.7. Other End Use
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Arbovirus Testing Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Arbovirus Testing Market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key Country Dynamics
    • 6.4.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.1.3. Competitive Scenario
    • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.2.3. Competitive Scenario
    • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Mexico Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Germany
    • 6.5.1.1. Key Country Dynamics
    • 6.5.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.1.3. Competitive Scenario
    • 6.5.1.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.2. U.K.
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.2.3. Competitive Scenario
    • 6.5.2.4. U.K. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Denmark
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.6.3. Competitive Scenario
    • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.7.3. Competitive Scenario
    • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Norway
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework/ Reimbursement Structure
    • 6.5.8.3. Competitive Scenario
    • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key Country Dynamics
    • 6.6.1.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.1.3. Competitive Scenario
    • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.2.3. Competitive Scenario
    • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.4. South Korea
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework/ Reimbursement Structure
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.2.3. Competitive Scenario
    • 6.7.2.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.7.3.3. Competitive Scenario
    • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.2.3. Competitive Scenario
    • 6.8.2.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.3.3. Competitive Scenario
    • 6.8.3.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.4.3. Competitive Scenario
    • 6.8.4.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework/ Reimbursement Structure
    • 6.8.5.3. Competitive Scenario
    • 6.8.5.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/ Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key Company Heat Map Analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Abbott
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial Performance
    • 7.4.1.3. Product Benchmarking
    • 7.4.1.4. Strategic Initiatives
  • 7.4.2. Thermo Fisher Scientific Inc.
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial Performance
    • 7.4.2.3. Product Benchmarking
    • 7.4.2.4. Strategic Initiatives
  • 7.4.3. NovaTec Immundiagnostica GmbH (Gold Standard Diagnostics Frankfurt GmbH)
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial Performance
    • 7.4.3.3. Product Benchmarking
    • 7.4.3.4. Strategic Initiatives
  • 7.4.4. Agilent Technologies, Inc.
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial Performance
    • 7.4.4.3. Product Benchmarking
    • 7.4.4.4. Strategic Initiatives
  • 7.4.5. EUROIMMUN Medical Laboratory Diagnostics AG
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial Performance
    • 7.4.5.3. Product Benchmarking
    • 7.4.5.4. Strategic Initiatives
  • 7.4.6. Merck KGaA
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial Performance
    • 7.4.6.3. Product Benchmarking
    • 7.4.6.4. Strategic Initiatives
  • 7.4.7. F. Hoffmann-La Roche Ltd
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial Performance
    • 7.4.7.3. Product Benchmarking
    • 7.4.7.4. Strategic Initiatives
  • 7.4.8. Siemens Healthineers AG
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial Performance
    • 7.4.8.3. Product Benchmarking
    • 7.4.8.4. Strategic Initiatives
  • 7.4.9. QIAGEN
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial Performance
    • 7.4.9.3. Product Benchmarking
    • 7.4.9.4. Strategic Initiatives
  • 7.4.10. Bio-Rad Laboratories, Inc.
    • 7.4.10.1. Company Overview
    • 7.4.10.2. Financial Performance
    • 7.4.10.3. Product Benchmarking
    • 7.4.10.4. Strategic Initiatives

관련자료